Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size, Status and Forecast 2021-2027

Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size, Status and Forecast 2021-2027

Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Tecemotide
1.2.3 Astuprotimut-R
1.2.4 Tertomotide
1.2.5 Nelipepimut-S
1.2.6 Others
1.3 Market by Application
1.3.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Pediatrics
1.3.3 Adults
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Perspective (2016-2027)
2.2 Common Cancer-associated Antigens (CAAs) Vaccine Growth Trends by Regions
2.2.1 Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Common Cancer-associated Antigens (CAAs) Vaccine Historic Market Share by Regions (2016-2021)
2.2.3 Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Regions (2022-2027)
2.3 Common Cancer-associated Antigens (CAAs) Vaccine Industry Dynamic
2.3.1 Common Cancer-associated Antigens (CAAs) Vaccine Market Trends
2.3.2 Common Cancer-associated Antigens (CAAs) Vaccine Market Drivers
2.3.3 Common Cancer-associated Antigens (CAAs) Vaccine Market Challenges
2.3.4 Common Cancer-associated Antigens (CAAs) Vaccine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Common Cancer-associated Antigens (CAAs) Vaccine Players by Revenue
3.1.1 Global Top Common Cancer-associated Antigens (CAAs) Vaccine Players by Revenue (2016-2021)
3.1.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share by Players (2016-2021)
3.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Common Cancer-associated Antigens (CAAs) Vaccine Revenue
3.4 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Concentration Ratio
3.4.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Common Cancer-associated Antigens (CAAs) Vaccine Revenue in 2020
3.5 Common Cancer-associated Antigens (CAAs) Vaccine Key Players Head office and Area Served
3.6 Key Players Common Cancer-associated Antigens (CAAs) Vaccine Product Solution and Service
3.7 Date of Enter into Common Cancer-associated Antigens (CAAs) Vaccine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Common Cancer-associated Antigens (CAAs) Vaccine Breakdown Data by Type
4.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Historic Market Size by Type (2016-2021)
4.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Type (2022-2027)
5 Common Cancer-associated Antigens (CAAs) Vaccine Breakdown Data by Application
5.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Historic Market Size by Application (2016-2021)
5.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2016-2027)
6.2 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type
6.2.1 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2016-2021)
6.2.2 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2022-2027)
6.2.3 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2016-2027)
6.3 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application
6.3.1 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2016-2021)
6.3.2 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2022-2027)
6.3.3 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2016-2027)
6.4 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country
6.4.1 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2016-2021)
6.4.2 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2016-2027)
7.2 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type
7.2.1 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2016-2021)
7.2.2 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2022-2027)
7.2.3 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2016-2027)
7.3 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application
7.3.1 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2016-2021)
7.3.2 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2022-2027)
7.3.3 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2016-2027)
7.4 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country
7.4.1 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2016-2021)
7.4.2 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2016-2027)
8.2 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type
8.2.1 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2016-2027)
8.3 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application
8.3.1 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2016-2027)
8.4 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region
8.4.1 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2016-2027)
9.2 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type
9.2.1 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2016-2021)
9.2.2 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2022-2027)
9.2.3 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2016-2027)
9.3 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application
9.3.1 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2016-2021)
9.3.2 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2022-2027)
9.3.3 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2016-2027)
9.4 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country
9.4.1 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2016-2021)
9.4.2 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2016-2027)
10.2 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type
10.2.1 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2016-2027)
10.3 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application
10.3.1 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2016-2027)
10.4 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country
10.4.1 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Seattle Genetics
11.1.1 Seattle Genetics Company Details
11.1.2 Seattle Genetics Business Overview
11.1.3 Seattle Genetics Common Cancer-associated Antigens (CAAs) Vaccine Introduction
11.1.4 Seattle Genetics Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2016-2021)
11.1.5 Seattle Genetics Recent Development
11.2 Merck Serono
11.2.1 Merck Serono Company Details
11.2.2 Merck Serono Business Overview
11.2.3 Merck Serono Common Cancer-associated Antigens (CAAs) Vaccine Introduction
11.2.4 Merck Serono Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2016-2021)
11.2.5 Merck Serono Recent Development
11.3 Merck KGaA
11.3.1 Merck KGaA Company Details
11.3.2 Merck KGaA Business Overview
11.3.3 Merck KGaA Common Cancer-associated Antigens (CAAs) Vaccine Introduction
11.3.4 Merck KGaA Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2016-2021)
11.3.5 Merck KGaA Recent Development
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Details
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Common Cancer-associated Antigens (CAAs) Vaccine Introduction
11.4.4 GlaxoSmithKline Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2016-2021)
11.4.5 GlaxoSmithKline Recent Development
11.5 KAEL-GemVax
11.5.1 KAEL-GemVax Company Details
11.5.2 KAEL-GemVax Business Overview
11.5.3 KAEL-GemVax Common Cancer-associated Antigens (CAAs) Vaccine Introduction
11.5.4 KAEL-GemVax Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2016-2021)
11.5.5 KAEL-GemVax Recent Development
11.6 SELLAS Life Sciences
11.6.1 SELLAS Life Sciences Company Details
11.6.2 SELLAS Life Sciences Business Overview
11.6.3 SELLAS Life Sciences Common Cancer-associated Antigens (CAAs) Vaccine Introduction
11.6.4 SELLAS Life Sciences Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2016-2021)
11.6.5 SELLAS Life Sciences Recent Development
11.7 Celldex
11.7.1 Celldex Company Details
11.7.2 Celldex Business Overview
11.7.3 Celldex Common Cancer-associated Antigens (CAAs) Vaccine Introduction
11.7.4 Celldex Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2016-2021)
11.7.5 Celldex Recent Development
11.8 Immatics Biotechnologies
11.8.1 Immatics Biotechnologies Company Details
11.8.2 Immatics Biotechnologies Business Overview
11.8.3 Immatics Biotechnologies Common Cancer-associated Antigens (CAAs) Vaccine Introduction
11.8.4 Immatics Biotechnologies Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2016-2021)
11.8.5 Immatics Biotechnologies Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Tecemotide
Table 3. Key Players of Astuprotimut-R
Table 4. Key Players of Tertomotide
Table 5. Key Players of Nelipepimut-S
Table 6. Key Players of Others
Table 7. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Regions (2016-2021)
Table 11. Global Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Regions (2022-2027)
Table 13. Common Cancer-associated Antigens (CAAs) Vaccine Market Trends
Table 14. Common Cancer-associated Antigens (CAAs) Vaccine Market Drivers
Table 15. Common Cancer-associated Antigens (CAAs) Vaccine Market Challenges
Table 16. Common Cancer-associated Antigens (CAAs) Vaccine Market Restraints
Table 17. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Players (2016-2021)
Table 19. Global Top Common Cancer-associated Antigens (CAAs) Vaccine Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Common Cancer-associated Antigens (CAAs) Vaccine as of 2020)
Table 20. Ranking of Global Top Common Cancer-associated Antigens (CAAs) Vaccine Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Common Cancer-associated Antigens (CAAs) Vaccine Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Common Cancer-associated Antigens (CAAs) Vaccine Product Solution and Service
Table 24. Date of Enter into Common Cancer-associated Antigens (CAAs) Vaccine Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share by Type (2016-2021)
Table 28. Global Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share by Application (2016-2021)
Table 32. Global Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2022-2027) & (US$ Million)
Table 64. Seattle Genetics Company Details
Table 65. Seattle Genetics Business Overview
Table 66. Seattle Genetics Common Cancer-associated Antigens (CAAs) Vaccine Product
Table 67. Seattle Genetics Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2016-2021) & (US$ Million)
Table 68. Seattle Genetics Recent Development
Table 69. Merck Serono Company Details
Table 70. Merck Serono Business Overview
Table 71. Merck Serono Common Cancer-associated Antigens (CAAs) Vaccine Product
Table 72. Merck Serono Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2016-2021) & (US$ Million)
Table 73. Merck Serono Recent Development
Table 74. Merck KGaA Company Details
Table 75. Merck KGaA Business Overview
Table 76. Merck KGaA Common Cancer-associated Antigens (CAAs) Vaccine Product
Table 77. Merck KGaA Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2016-2021) & (US$ Million)
Table 78. Merck KGaA Recent Development
Table 79. GlaxoSmithKline Company Details
Table 80. GlaxoSmithKline Business Overview
Table 81. GlaxoSmithKline Common Cancer-associated Antigens (CAAs) Vaccine Product
Table 82. GlaxoSmithKline Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2016-2021) & (US$ Million)
Table 83. GlaxoSmithKline Recent Development
Table 84. KAEL-GemVax Company Details
Table 85. KAEL-GemVax Business Overview
Table 86. KAEL-GemVax Common Cancer-associated Antigens (CAAs) Vaccine Product
Table 87. KAEL-GemVax Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2016-2021) & (US$ Million)
Table 88. KAEL-GemVax Recent Development
Table 89. SELLAS Life Sciences Company Details
Table 90. SELLAS Life Sciences Business Overview
Table 91. SELLAS Life Sciences Common Cancer-associated Antigens (CAAs) Vaccine Product
Table 92. SELLAS Life Sciences Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2016-2021) & (US$ Million)
Table 93. SELLAS Life Sciences Recent Development
Table 94. Celldex Company Details
Table 95. Celldex Business Overview
Table 96. Celldex Common Cancer-associated Antigens (CAAs) Vaccine Product
Table 97. Celldex Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2016-2021) & (US$ Million)
Table 98. Celldex Recent Development
Table 99. Immatics Biotechnologies Company Details
Table 100. Immatics Biotechnologies Business Overview
Table 101. Immatics Biotechnologies Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2016-2021) & (US$ Million)
Table 102. Immatics Biotechnologies Recent Development
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Type: 2020 VS 2027
Figure 2. Tecemotide Features
Figure 3. Astuprotimut-R Features
Figure 4. Tertomotide Features
Figure 5. Nelipepimut-S Features
Figure 6. Others Features
Figure 7. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Application: 2020 VS 2027
Figure 8. Pediatrics Case Studies
Figure 9. Adults Case Studies
Figure 10. Common Cancer-associated Antigens (CAAs) Vaccine Report Years Considered
Figure 11. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Regions: 2020 VS 2027
Figure 14. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Regions (2022-2027)
Figure 15. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Players in 2020
Figure 16. Global Top Common Cancer-associated Antigens (CAAs) Vaccine Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Common Cancer-associated Antigens (CAAs) Vaccine as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Common Cancer-associated Antigens (CAAs) Vaccine Revenue in 2020
Figure 18. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share by Type (2016-2021)
Figure 19. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share by Type (2022-2027)
Figure 20. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Type (2016-2027)
Figure 22. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Application (2016-2027)
Figure 23. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Country (2016-2027)
Figure 24. United States Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Type (2016-2027)
Figure 28. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Application (2016-2027)
Figure 29. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Country (2016-2027)
Figure 30. Germany Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Region (2016-2027)
Figure 40. China Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Type (2016-2027)
Figure 48. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Application (2016-2027)
Figure 49. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Country (2016-2027)
Figure 50. Mexico Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Country (2016-2027)
Figure 56. Turkey Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Seattle Genetics Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2016-2021)
Figure 60. Merck Serono Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2016-2021)
Figure 61. Merck KGaA Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2016-2021)
Figure 62. GlaxoSmithKline Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2016-2021)
Figure 63. KAEL-GemVax Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2016-2021)
Figure 64. SELLAS Life Sciences Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2016-2021)
Figure 65. Celldex Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2016-2021)
Figure 66. Immatics Biotechnologies Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2016-2021)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Nuclear Medicine Cyclotron Systems Market Report, History and Forecast 2018-2029

Published: 11-Jan-2024        Price: US 3350 Onwards        Pages: 118

The global Nuclear Medicine Cyclotron Systems market was valued at US$ 220.85 million in 2022 and will reach US$ 283.75 million by the end of 2029, growing at a CAGR of 4.38% during 2023-2029. Asia-Pacific market for Nuclear Medicine Cyclotron Systems was valued at $ 61.16 million in 2022 and will reach $ 104.22 million by 2029, at a CAGR of 5.84% during the forecast period of 2023 through 2029. Report Scope This report aims to provide a comprehensive presentation of the glo......

Global Non-imaging Diagnostic Catheter Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 95

The global Non-imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......

Global Imaging Diagnostic Catheter Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 90

The global Imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated......

Global PCR Equipment Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 77

The global PCR Equipment market was valued at US$ 806 million in 2023 and is anticipated to reach US$ 1230.7 million by 2030, witnessing a CAGR of 6.7% during The forecast period 2024-2030. PCR (Polymerase Chain Reaction) equipment is widely used in molecular biology and genetics research for amplifying DNA and RNA sequences. The market for PCR equipment is influenced by several key drivers. Here are some of The significant market drivers: Advancements in Research and Diagnost......

Global Disposable Sterile Syringes and Needles Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 109

The global Disposable Sterile Syringes and Needles market was valued at US$ 404.4 million in 2023 and is anticipated to reach US$ 539.1 million by 2030, witnessing a CAGR of 2.1% during The forecast period 2024-2030. North American market for Disposable Sterile Syringes and Needles is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Disposable Sterile Syringes and N......

Global Orthopaedic Power Tools Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106

The global Orthopaedic Power Tools market was valued at US$ 463.3 million in 2023 and is anticipated to reach US$ 746.5 million by 2030, witnessing a CAGR of 7.3% during The forecast period 2024-2030. North American market for Orthopaedic Power Tools is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Orthopaedic Power Tools is estimated to increase from $ million i......

Global Cerebrospinal Fluid Management Devices Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Cerebrospinal Fluid Management Devices market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Cerebrospinal Fluid Management Devices is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Cerebrospinal Fluid Management Devices is estimate......

Global CAD & CAM Milling Burs Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 79

The global CAD & CAM Milling Burs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ ......

Global Artificial Teeth Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 98

The global Artificial Teeth market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, a......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs